tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Teva Pharmaceutical (TEVA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCYResearch Report) and Teva Pharmaceutical (TEVAResearch Report).

Incyte (INCY)

Evercore ISI analyst Maneka Mirchandaney maintained a Buy rating on Incyte yesterday and set a price target of $90.00. The company’s shares closed last Wednesday at $68.28.

According to TipRanks.com, Mirchandaney is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -24.3% and a 22.2% success rate. Mirchandaney covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Codiak BioSciences, and Bionomics Ltd ADR.

Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $90.36, which is a 35.2% upside from current levels. In a report issued on February 8, Truist Financial also reiterated a Buy rating on the stock with a $95.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Teva Pharmaceutical (TEVA)

Evercore ISI analyst Umer Raffat maintained a Hold rating on Teva Pharmaceutical yesterday. The company’s shares closed last Wednesday at $8.99.

According to TipRanks.com, Raffat is a 1-star analyst with an average return of -4.7% and a 46.4% success rate. Raffat covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals, Inc., Atea Pharmaceuticals, and Gilead Sciences.

Currently, the analyst consensus on Teva Pharmaceutical is a Hold with an average price target of $11.00, implying a 30.6% upside from current levels. In a report issued on January 27, Argus Research also downgraded the stock to Hold.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on INCY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed